Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax

By Contract Pharma Staff | 07.28.20

Dalton to provide formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early phase clinical trials.

Dalton Pharma Services has partnered with the University of Saskatchewan’s Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO-InterVac) in their effort to develop a vaccine for COVID-19. Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.

On April 23rd, the Canadian Federal government committed $1.1 billion to support COVID-19 vaccine research and clinical trials. VIDO-InterVac has made significant progress in their COVID-19 vaccine development with funding from both the federal government and Government of Saskatchewan, and hope to initiate clinical trials of their vaccine in 4Q20.

“Dalton is pleased to apply its expertise in aseptic formulation and sterile fill/finish towards developing this leading-edge therapy. We look forward to working with VIDO-InterVac in support of their efforts to develop an effective vaccine for COVID-19,” said Peter Pekos, CEO of Dalton Pharma Services.

Dr. Volker Gerdts, Director and CEO of VIDO-InterVac, stated, “The development of an effective COVID-19 vaccine is of utmost urgency and VIDO-InterVac is excited to have Dalton as a trusted partner as we work together on this critical initiative.”